Seattle, WA (PRWEB) April 22, 2011
InBios International, Inc. releases the DENV Detect IgM Capture ELISA. It is the first test cleared to market by the FDA to help diagnose dengue fever.
Each year over 100 million dengue cases occur in the tropical and subtropical areas of the world. Most reported cases in the United States are from individuals returning from travels to those areas. More recently dengue has also been associated with a number of outbreaks in Hawaii, Texas and Florida.
InBios' kit was developed with a new generation of CDC licensed recombinants expressed in mammalian cells. The performance of the DENV Detect IgM Capture ELISA was thoroughly evaluated in retrospective and prospective studies. These studies were performed at multiple field sites with clinically confirmed cases of Dengue 1-4 serotypes. The development of the kit was supported in part by NIH SBIR grant R43AI074172.
InBios International, Inc. is a medical diagnostic company that specializes in developing and manufacturing medical diagnostic tests for the detection of infectious diseases. Since its inception in 1996, InBios has developed proprietary technologies useful in the development of ELISA and rapid based immunodiagnostic assays. It has also licensed antigens from major corporations and research organizations from which a number of its assays have been developed.
Information concerning this kit can be obtained by emailing info(at)inbios(dot)com or visit the InBios website at http://www.inbios.com.